Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes
In a metastatic setting, low Ki-67 and moderate-to-severe neutropenia are associated with better survival outcomes in endocrine resistant patients treated with palbociclib (Clinical trial registration: www.clinicaltrials.gov identifier is NCT06338644).
Authors
- Yasmine Magdy Fahim Genina (ORCID: https://orcid.org/0000-0002-1131-7594)
- Abdel‐Hameed Ibrahim Mohamed Ebid (ORCID: https://orcid.org/0000-0002-9072-0815)
- Sara Mohamed Mohamed Abdelmotaleb (ORCID: https://orcid.org/0000-0003-0836-3706)
- Hesham Haffez (ORCID: https://orcid.org/0000-0002-9924-2063)
- Loay Kassem (ORCID: https://orcid.org/0000-0001-6559-5867)
- Sherif Hassanien Ahmed Hakam
Institutions
- Ain Shams University (EG)
- Cairo University (EG)
- Helwan University (EG)
Publication Details
- Journal
- Expert Review of Anticancer Therapy
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1080/14737140.2025.2560941
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00